▲ +212.50% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Aileron Therapeutics in the last 3 months. The average price target is $3.50, with a high forecast of $5.00 and a low forecast of $2.00. The average price target represents a 212.50% upside from the last price of $1.12.
The current consensus among 3 investment analysts is to buy stock in Aileron Therapeutics. This Buy consensus rating has held steady for over two years.
Aileron Therapeutics, Inc. operates as a clinical stage chemoprotection oncology company in the United States. The company is developing ALRN-6924, which is in Phase 1 trial for solid tumor and lymphoma; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); Phase 1b trial to test the combination of ALRN-6924 and cytarabine, or Ara-C, in patients with MDS; and a Phase 2a combination trial of ALRN-6924 and palbociclib in patients with tumors harboring MDM2 amplifications co-amplifications, as well as for patients with p53-mutated small cell lung cancer that has completed Phase 1b clinical trial. Aileron Therapeutics, Inc. has a license agreement with Dana-Farber Cancer Institute and Harvard College; and Umicore Precious Metals Chemistry USA, LLC. The company was formerly known as Renegade Therapeutics, Inc. and changed its name to Aileron Therapeutics, Inc. in February 2007. Aileron Therapeutics, Inc. was incorporated in 2001 and is based in Watertown, Massachusetts.